Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients. CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis. Cosentyx has been approved for the treatment of PsA in Japan since December 2014 and has received approval in 49 countries worldwide for the treatment of moderate-to-severe plaque psoriasis. 2016 Novartis AG. Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients (NOVN.VX). Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients.
(MHLW) approved Cosentyx(TM) (secukinumab, formerly known as AIN457), for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who are not adequately responding to systemic therapies (except for biologics). The positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending Cosentyx as a first-line treatment of moderate-to-severe psoriasis patients in Europe was obtained in November 2014. Press Release: Novartis Receives Positive CHMP Opinion for the First IL-17A Inhibitor Cosentyx to Treat Ankylosing Spondylitis and Psoriatic Arthritis. Novartis announced today that the European Commission (EC) has approved Cosentyx (secukinumab). Switzerland: Novartis Receives Two Landmark European Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis. These approvals follow on from the earlier EC approval of Cosentyx for the first-line treatment of patients with moderate-to-severe plaque psoriasis. (Source: Novartis AG ) Global phase IIIb head-to-head study of secukinumab versus Stelara in moderate-to-severe plaque psoriasis has started patient enrollment CLEAR is a.
Use (CHMP) has provided a positive opinion on the approval of Cosentyx (secukinumab, formerly known as AIN457). Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth read more By: Nasdaq / GlobenewsWire – 21 Apr 2016Related companies: Novartis International AG Genomics Institute of the Novartis Research Foundation Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth. Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis Biopharmaceuticals FDA. Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan’s Over-the-Counter Business Biopharmaceuticals Personnel. Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Biopharmaceuticals Oncology. ThromboGenics Receives Positive CHMP Opinion for JETREA(R) Biopharmaceuticals Ophthalmology Regulatory.